Darifenacin Hydrobromide
4 NDCs across 1 manufacturer|4 Generic,0 Brand
Darifenacin Hydrobromide is used to treat overactive urinary bladder and urge urinary incontinence, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Dec 22, 2004, and the first generic was approved Mar 13, 2015. FDA's Orange Book lists 12 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $7 million on Darifenacin Hydrobromide across 38,000 claims for 10,000 beneficiaries.
Darifenacin Hydrobromide is available as 4 NDCs from 1 manufacturer (4 generic, 0 brand), with NADAC prices from $0.43 to $0.55 per EA — a 27% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
4
4G / 0B
Manufacturers
1
competing in market
Price Spread
$0.43 – $0.55
per EA
7d Activity
avg +2.1% WoW · of 4 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Cipla USA Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Cholinergic Muscarinic Antagonist class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing DARIFENACIN HYDROBROMIDE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
DARIFENACIN ER 7.5 MG TABLET | $0.5494 per EA | -4.65% |
DARIFENACIN ER 7.5 MG TABLET | $0.5494 per EA | -4.65% |
DARIFENACIN ER 15 MG TABLET | $0.4323 per EA | +8.87% |
DARIFENACIN ER 15 MG TABLET | $0.4323 per EA | +8.87% |
Frequently Asked Questions
What is Darifenacin Hydrobromide used to treat?
Darifenacin Hydrobromide is used to treat overactive urinary bladder and urge urinary incontinence, per the National Library of Medicine's MED-RT classification.
When did Darifenacin Hydrobromide become available as a generic?
FDA approved the first generic Darifenacin Hydrobromide (ANDA) on Mar 13, 2015. The Orange Book currently lists 12 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Darifenacin Hydrobromide?
In 2024, Medicare Part D spent $7 million on Darifenacin Hydrobromide across 38,000 claims for 10,000 beneficiaries.
How many Darifenacin Hydrobromide products are on the market?
The Darifenacin Hydrobromide drug market contains 4 NDCs from 1 manufacturer — 4 generic and 0 brand products.
What is the price range for Darifenacin Hydrobromide?
NADAC reference prices for Darifenacin Hydrobromide range from $0.4323 to $0.5494 per EA — a 27% difference between cheapest and most expensive.
Which manufacturers make Darifenacin Hydrobromide?
1 manufacturer lists Darifenacin Hydrobromide in NADAC. Ranked by number of NDCs, the largest are Cipla USA Inc. (4).
How has the price of Darifenacin Hydrobromide changed recently?
Over the past 7 days, 2 Darifenacin Hydrobromide NDCs rose and 2 fell, with a market-wide average change of +2.1%.